Professional Documents
Culture Documents
Andi Poster
Andi Poster
BACKGROUND
The favourable safety and efficacy data from in vitro studies and open trials of
fractionated neem leaf extract (irab)1-7, combined with the long history of traditional
use and efficacy of neem extracts in malaria, indicate the need to conduct a
randomized clinical trial of irab in malaria. This need is underscored by the increasing
incidence of resistance to, and/ or the lack of tolerability/ safety of the currently
available antimalarial drugs.
Rationale
The development of a fractionated, refined neem leaf extract offers the prospect of
harnessing the therapeutic potential of an ancient traditional medicine, while avoiding
the hepatotoxicity of the crude traditional formulations4,6,7.
Apart from schizonticidal and gametocytocidal effects in malaria6,7, irab also
blocks the adhesion of parasitized erythrocytes to the capillary endothelium in
malaria4,5. This multipronged mode of action in malaria would make it difficult for
Plasmodium falciparum to evolve resistance: in spite of millennia of traditional use
for “fevers” including malaria, neem preparations have retained their efficacy without
the need to resort to combination chemotherapy.
By blocking cell surface adhesion receptors, irab offers the prospect of
antineoplastic and antiviral actions (i.e. viral entry blockade) as well5. A particular
advantage of irab, suggested by in vitro and clinical observations, is combined
antiretroviral and antimalarial efficacy. This would thwart the synergistic comorbidity
of malaria and HIV infection9,10.
STUDY OBJECTIVES
Primary Objective:
The primary objective is to confirm the hypothesis that irab is non-inferior
to artemether-lumefantrine, in the treatment of symptomatic, uncomplicated malaria
due to P. falciparum.
Secondary Objectives:
To assess:
1 Efficacy (asexual parasite clearance rate) of irab at Day 28;
2 Safety and tolerability for both treatment regimens;
3 % Early treatment failures;
4 % Late treatment failures;
5 % Late clinical failure
6 % Late parasitological failure (LPF)
7 % Adequate clinical and parasitological response (ACPR)
8 Clinical cure rates at 3, 7, 14 & 28 days;
9 Asexual parasite clearance rate at 7,14, 21 & 28 days;
10 Gametocyte clearance rate at 7, 14, 21 & 28 days;
11 Fever clearance time;
12 Asexual parasite clearance time.
13 To compare the clinical efficacy of irab to that of standard artemisinin
combination therapy (ACT, artemether-lumefantrine).
METHODS
STUDY DESIGN
General organization
The clinical study will be carried out in 360 eligible subjects with proven P.
falciparum malaria infection. They will be treated with irab formulated into capsule
form and given orally at a dose of 20 mg/kg (750 mg bd for 75 kg adult) daily for four
days. Daily thick and thin smears shall be made on Days 0, 1, 2, 3, 7, 14, 21 and 28 to
detect the presence of P. falciparum parasites. Safety of the product shall be
monitored clinically, haematologically and biochemically. 120 volunteers shall be
recruited for the study per centre: 60 on irab and 60 on artemether-lumefantrine. The
design for the trial is double blind, three centres, randomized, comparative, parallel
group study using patients with acute but uncomplicated malaria.
Inclusion criteria
Adults i.e. 18 years and above, who present at the study centres with a recent history
of fever and a positive smear (parasitaemia of 1,000 to 100,000 per mm3)
Both Male and Female
Uncomplicated P. falciparum malaria, i.e. no evidence of danger sign
[neurological involvement, haemolysis or renal impairment].
Not taken any antimalarial drug in the past 7 days
Haemoglobin greater than 5 grammes per dl
PCV > 15%
Willingness to participate in the study as will be indicated by informed written
consent.
Ability to take drug orally.
Serum glucose > 40 mg/dL (fingerprick test or peripheral blood)
Exclusion criteria
Age range: less than 18 years
Complicated malaria i.e. evidence of danger sign [cerebral involvement (meningitis or
encephalitis), vomiting, haemolysis, dehydration, renal involvement].
Severe underlying disease requiring specific therapeutic intervention.
Haemoglobin less than 5 grams per dl or PCV < 15%
Parasitaemia greater than 200,000 per mm3 of blood.
No written consent to participate in the study
Serious medical conditions such as hypertension, diabetes and AIDS.
Treatment phase
The sequence of contact period for symptomatic assessment and adverse effects
monitoring shall be on Days 0, 1, 2, 3, 7, 14, 21 and 28. Each subject will be admitted
for a period of three days as an in-patient in the hospital. Recruitment and registration
of volunteers for the study will vary at the different study centres due to logistics and
availability of eligible subjects. Thus, the duration for the study may span 6-12
months. This will include follow up and all necessary assessments as the need may
arise.
Randomization
The total number of subjects to be enrolled per centre in the study is 120. All study
drugs will be administered as blinded therapy. Subjects will be randomized in equal
numbers to one of the following two regimens:
IRAB 20mg/kg/day PO (three 250 mg caps two times daily for four days:
Days 0,1,2,3)
and matching placebo of artemether-lumefantrine four (20/120 mg tabs) stat, repeated
after 8h, 24h and 48h (Days 0, 1, 2)
(Irab will be supplied as formulated capsules to be administered orally in doses of 20
mg/kg daily one hour before meals morning and evening for four days.)
OR
Matching placebo for IRAB 20mg/kg/day PO (three 250 mg caps two times daily for
four days: Days 0, 1, 2, 3)
And artemether-lumefantrine four (20/120 mg tabs) stat, repeated after 8h, 24h and
48h (Days 0, 1, 2)
Serum Chemistry and Haematology: This will be repeated on Days 7 and 28 and will
include the same tests as listed above.
Treatment failures
All treatment failures shall be treated with either quinine or an artemisinin
(amodiaquine-artesunate combination, or artemether-doxycycline if pregnancy
excluded).
DATA MANAGEMENT
Assessment of Efficacy
Determining the time taken to achieve negative blood slide and to be
asymptomatic will assess efficacy. The following definitions will be used:
(a) Complete cure = Complete aparasitaemia by day 7;
(b) Partial cure = Malaria parasite count dropped by at least 25% of
baseline by day 7;
(c) No cure/treatment failure = No change in parasite count from baseline
or increase is observed by day 3, or whenever withdrawn from the trial.
Assessment of Safety
This will be done by comparing the baseline haematology parameters,
biochemistry parameters and vital/physical signs with those obtained at
subsequent follow-up visits. The following definitions of adverse effects will be
used:
(a) Mild - Tolerable, patient active and able to conduct his normal
business efficiently
(b) Moderate - Causes discomfort, but still able to conduct normal
activities with decreased efficiency.
(c) Severe - Interferes with the patient's activities.
DISCUSSION/ CONCLUSIONS
Thus preliminary studies indicate the following advantages of irab (as compared to
other currently available antimalarial drugs), which need to be confirmed in a
randomized controlled clinical trial:
a) triple mode of action in malaria (from the in vitro studies quoted above):
schizonticidal, gametocytocidal and anticytoadhesion. Such a multipronged attack on
Plasmodium would make the likelihood of development of resistance less than with
conventional drugs which have a single mode of action. Hence there would be less
need for combination therapy with irab as compared to the single-mode-of-action
drugs.
c) convenient twice daily oral dosing regimen: this would help promote patient
adherence to treatment regimens.
d) affordability: being a neem leaf extract, irab is relatively cheap to produce, and this
represents a distinct advantage over relatively expensive imported conventional drugs.
f) a regimen which could be easily adapted for pediatric use (neem leaf preparations
have been used extensively in children), and
g) a potentially efficacious and safe therapy with relatively few side effects, for
pregnant women with chloroquine-resistant P. falciparum.
Irab has a particularly promising role to play in pregnant women both for the
prophylaxis and treatment of malaria. Unlike the antifolate prophylactics, there would
not be the worry of an adverse effect on nucleotide metabolism in the embryo, which
might influence the likelihood of neural tube defects. The anticytoadhesion efficacy
makes irab a drug of choice to combat the sequestration of malaria parasites in the
placental microcirculation, which mediates much of the morbidity and fetal mortality
in malaria. In a few case reports of pregnant women with HIV infection who have
relied on irab treatment, there was effective prevention of malaria during pregnancy,
and prevention of mother to child transmission of HIV (Udeinya, personal
communication).
BIBLIOGRAPHY
3. Badam L, Deolankar RP, Kulkarni MM, Nagsampgi BA, Wagh UV. In vitro
antimalarial activity of neem (Azadirachta indica A. Juss) leaf and seed extracts.
Indian J. Malaria 1987; 24: 111-117
5. Udeinya I.J., Mbah A.U., Chijioke C.P., Shu E.N. An antimalarial extract from
neem leaves is antiretroviral. Trans Roy Soc Trop Med Hyg 2004; 95: 435–437.
8. Shu EN, Mbah AU, Udeinya IJ, Chijioke CP, Nubila T, Udeinya F, Muobuike A,
Mmuobieri A, Obioma MS. Fractionated neem leaf extract is safe and increases CD4+
cell levels in HIV/AIDS patients. Am. J. Therap. 2007; 14: 369-374.
10. Kublin JG, Steketee RW. HIV infection and malaria: understanding the
interactions. J. Infect. Dis. 2005; 193: 1-3